Marisa Wexler, MS,  senior science writer—

Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis (CF) who have liver involvement, new data indicate. “We detected improvements in validated noninvasive biomarkers of liver fibrosis [scarring] and cirrhosis in children and adolescents treated with” these therapies, the…

Treatment with Trikafta can help people with cystic fibrosis (CF) to put on weight, according to new data from a small clinical trial. These findings indicate that traditional guidelines for CF nutrition — which urge a…

Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic fibrosis (CF) who are unable to benefit from current treatments, effectively increased CFTR gene activity in a ferret model of the disease, the company reported. Katherine Excoffon, PhD,…

Since the approval of Trikafta in the U.S., Nationwide Children’s Hospital in Ohio has seen a steep increase in the number of women with cystic fibrosis (CF) choosing to become pregnant. “Due to the large pregnancy volume we…

A platform to help people with cystic fibrosis (CF) better adhere to inhalation treatment, called the CFHealthHub, led to a substantial increase in the number taking medications as directed, according to a yearlong study. Although no benefits in lung function or pulmonary exacerbations were detected relative to usual care,…

Health Canada has granted priority review to an application that seeks to expand the approval of Trikafta to cover children with cystic fibrosis (CF) as young as 6 years. “We are pleased that [the application] has been accepted for Priority Review by Health Canada and we look forward…

Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution, a new study reveals. “A long-standing lore in the cystic fibrosis field says that each patient’s infection tells a unique story, and that Pseudomonas evolves in unpredictable ways,” Jennifer Bomberger, PhD, said…

Treatment with LungFit GO, an inhaled form of nitric oxide that can be self-administered at home, has so far been well-tolerated in a pilot clinical trial testing the investigational medication in adults with or without cystic fibrosis (CF). The ongoing trial involves patients with lung infections caused by…

The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic research center (SRC) dedicated to studying gene editing as a potential treatment strategy for cystic fibrosis (CF). “Making gene editing a reality for people with CF will take the…

The school closures, at-home confinements and other safety measures necessitated by the COVID-19 pandemic have caused less anxiety among children with cystic fibrosis (CF) than age-matched peers without the disease, a survey study in Turkey found. Children and teenagers with CF “seem to show more resilience in coping with…